Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
According to Zacks, “Phreesia Inc. provides a patient intake management platform. The company’s SaaS platform engages patients in their care and provides a modern, consistent experience, while enabling healthcare organizations to optimize their staffing, boost profitability and enhance clinical care. Phreesia Inc. is based in New York. “
A number of other equities research analysts also recently weighed in on the company. Piper Jaffray Companies set a $33.00 target price on Phreesia and gave the stock a “buy” rating in a research report on Tuesday, September 10th. JPMorgan Chase & Co. assumed coverage on Phreesia in a research report on Tuesday, August 13th. They set an “overweight” rating and a $33.00 price objective for the company. Robert W. Baird assumed coverage on Phreesia in a research report on Thursday, October 10th. They set an “outperform” rating and a $31.00 price objective for the company. William Blair assumed coverage on Phreesia in a research report on Monday, August 12th. They set an “outperform” rating for the company. Finally, Chardan Capital assumed coverage on Phreesia in a research report on Tuesday, July 23rd. They set a “buy” rating and a $33.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $30.60.
PHR traded down $0.26 during trading on Thursday, reaching $29.70. The stock had a trading volume of 119,587 shares, compared to its average volume of 272,714. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.52 and a quick ratio of 3.52. Phreesia has a 1-year low of $22.05 and a 1-year high of $31.00. The stock has a 50 day simple moving average of $27.07.
Phreesia (NYSE:PHR) last released its earnings results on Monday, September 9th. The company reported ($10.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($10.30). The business had revenue of $30.82 million during the quarter, compared to analysts’ expectations of $30.05 million. Equities analysts expect that Phreesia will post -0.56 EPS for the current fiscal year.
Several large investors have recently made changes to their positions in the company. Russell Investments Group Ltd. acquired a new stake in shares of Phreesia during the 3rd quarter valued at $47,000. Tower Research Capital LLC TRC acquired a new stake in shares of Phreesia during the 3rd quarter valued at $68,000. Rhumbline Advisers acquired a new stake in shares of Phreesia during the 3rd quarter valued at $208,000. Dean Capital Investments Management LLC acquired a new stake in shares of Phreesia during the 3rd quarter valued at $580,000. Finally, Emerald Advisers LLC acquired a new stake in shares of Phreesia during the 3rd quarter valued at $1,036,000. Institutional investors own 0.03% of the company’s stock.
Phreesia Company Profile
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company's Phreesia Platform offers a suite of solutions to manage the patient intake process and an integrated payments solution for processing of patient payments.
Featured Article: Dead Cat Bounce
For more information about research offerings from Zacks Investment Research, visit Zacks.com